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Chaperonehosphatidyl-inositol anchored glycoprotein localized on the surface and within a
variety of cells. Its conformation change is thought to be essential for the proliferation of prion
neurodegenerative diseases. Using the yeast two-hybrid assay we identiﬁed an interaction between prion
protein and clusterin, a chaperone glycoprotein. This interaction was conﬁrmed in a mammalian system by in
vivo co-immunoprecipitation and in vitro by circular dichroism analysis. Through deletion mapping analysis
we demonstrated that the α subunit, but not the β subunit, of clusterin binds to prion and that the C-
terminal 62 amino acid segment of the putative α helix region of clusterin is essential for the binding
interaction. The full prion protein as well as the N-terminal section (aa 23–95) and C-terminal (aa 96–231)
were shown to interact with clusterin. These ﬁndings provide new insights into the molecular mechanisms of
interaction between prion and clusterin protein and contribute to the understanding of prion protein's
physiological function.
Published by Elsevier B.V.1. Introduction
Prion diseases [1], also known as transmissible spongiform
encephalopathies (TSEs), are a group of fatal neurodegenerative
disorders that include Creutzfeldt–Jakob disease (CJD) and its variant
form (vCJD) in humans [2], bovine spongiform encephalopathy (BSE)
or mad cow disease in cattle, scrapie in sheep, and chronic wasting
disease (CWD) in deer [3]. In afﬂicted organisms the central nervous
system accumulates increased levels of a pathological isoform
(PrPtse) of the naturally occurring prion protein (PrPc). PrPtse is
more resistant to degradation and forms aggregates and amyloid
ﬁbrils. The normal PrPc protein contains mainly an α helix structure
whereas in the PrPtse isoform the β sheet conformation predomi-
nates. The mature human PrPc contains amino acids (aa) 23–231 and
is generated by a cleavage of the N-terminal signal peptide residues
1–22 and removal of the C-terminal hydrophobic peptide residues
232–253 in a transamidation reaction which attaches a glycosyl-
phosphatidyl-inositol (GPI) moiety to a terminal serine amino acid of
mature PrPc. The GPI anchor attaches the PrPc to cellular membranes
throughout the cell including the cell surface outer membrane.
Further post-translational modiﬁcations include glycosylation at
two conserved asparagine sites [4] of the C-terminal PrPc and resultrticle have not been formally
d should not be construed to
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tal).
.V.in three PrPc glycoforms (unglycosylated, monoglycosylated, and
diglycosylated).
PrPc is widely expressed in many tissues, with the highest
expression in the central nervous system (CNS) and the peripheral
nervous system (PNS). Despite decades of research, the physiological
function of PrPc is still not fully elucidated. PrPc knockout mice [5,6]
and cow [7] develop normally, but are resistant to PrPtse infection in
vivo and in vitrowhich demonstrates the essential role of PrPc in prion
diseases. One approach to characterize the physiological role of the
PrPc is to identify its ligands. Several studies have demonstrated with
either the bacterial or yeast two-hybrid system (Y2H) that cellular
chaperone proteins Hsp60 [8], αB-crystalline [9] Rdj2 [10], and other
group proteins such as TREK-1 [11], NRAGE [12], synapsin Ib, Pint1,
Grb2 [13], laminin receptor [14] and Bcl-2 [15] are prion-binding
ligands. Based on these observations, certain functions of PrPc have
been proposed. These include protection against apoptotic and
oxidative stress, cellular binding and uptake of copper ions,
transmembrane signaling maintenance of synapses, and adhesion to
the extracellular matrix [16].
In this study, we used a yeast two-hybrid system to demonstrate
that clusterin, a chaperone protein, can directly interact with PrPc.
These interactions were further supported by in vivo co-immuno-
precipitation and in vitro circular dichroism (CD) analysis. Our
study expands on previous ﬁndings of possible role of clusterin in
TSEs [17–19], provides new insights into the molecular mechanisms
of interaction between PrPc and its ligands and expands
our understanding of PrPc's functions in normal physiological
conditions.
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The Matchmaker Two-Hybrid System 3 (Clontech, Palo Alto, CA,
USA) was used to detect protein–protein interactions. All primers and
plasmids used in this study are listed in Tables 1 and 2, respectively.
2.1. Yeast two-hybrid prion plasmids
2.1.1. Bait prion plasmid pFX2
Human PrPc encoding the mature prion amino acid 23–231
sequence was ampliﬁed by polymerase chain reaction (PCR) with
primers FXF1 and FXR1 from human genomic DNA. The ampliﬁed
PrP23–231 DNA was cloned into pGEM3Z vector (Promega, Madison,
WI, USA), yielding the pFX1 plasmid. The PrP23–231 DNA was further
cloned into pGBKT7, a GAL4 DNA-binding domain (DNA-BD) vector
from Clontech, yielding the bait construct pFX2. This pFX2 was
transformed into yeast Saccharomyces cerevisiae AH109 (MAT a)
(Clontech), yielding the prion bait yeast AH109 [pFX2].
2.1.2. PrP23–95 plasmid pFX33
Plasmid pFX2 containing PrP23–231 was cut with PstI to get rid of
the prion coding region 96–231. The resulting large fragment was self
ligated to obtain the plasmid pFX33 which contained the prion
N-terminal amino acids 23–95 (PrP23–95).
2.1.3. PrP95–231 plasmid pFX70
A fragment containing prion coding region C-terminal amino acids
95–231 was isolated from plasmid pFX2 cut with PstI. This PrP95–231
fragment was subsequently cloned into pGBKT7 cut with PstI to obtain
the plasmid pFX70.
2.2. Yeast two-hybrid screen
The pray yeast S. cerevisiae Y187 (MAT α) pretransformed with
human adult brain cDNA library expressed as a fusion to the GAL4
activation domain (AD) in vector pGADT7-Rec (Clontech) was mated
with the bait yeast AH109 [pFX2]. The resulting library mating diploid
mixture was screened on synthetic dropout (SD) medium in the
absence of four nutrients (leucine, tryptophan, adenine, and histidine)
and further conﬁrmed on X-α-Gal medium, indicator plate for MEL1
(α-galactosidase regulated by GAL4) response. The inserted cDNA
fragments of positive clones from the human brain library screenwere
ampliﬁed directly from yeast colonies with PCR using pGADT7-Rec
primer FXF3 and FXR3. The resulting PCR products were directly
sequenced and compared to the DNA database at the National Center






FXF3 TGAAGATACCCCACCAAACC – pGADT7
FXR3 GCACGATGCACAGTTGAAGT – pGADT7
FXF1 AAATCGGAATTCAAGAAGCGCCCGAAGCCTGG EcoRI PRNP (23)
FXR1 TTTAGCGGATCCGCTCGATCCTCTCTGGTAATAGG BamHI PRNP (23)
FX21F AAGGATCCATGAATTCGACCAGACGGTCTCAGACAATG BamHI CLU (23)
FX21R AACTCGAGTCGACCGGACGATGCGGGACTTGGGA XhoI CLU (227)
FX22F ATAGGATCCatGAATTCATACGAGAAGGCGAC BamHI CLU (273)
FX22R ATACTCGAGTCGACTCACTCCTCCCGGTGCTTTTT XhoI CLU (449)
FX23F ATAGGATCCTCACGCAAGGCGAAGACCAG BamHI CLU (375)
FX25F ATAGGATCCATAGCTTGATGCCCTTCTCTCCG BamHI CLU (228)
FX27F ATAGGATCCATCAGGCTAAGCTGCGGCGGGAGC BamHI CLU (320)
FX28F ATAAGGATCCATACCAACAACCCCTCCCAGGC BamHI CLU (314)
FX28R ATAACTCGAGTCGACTGGTAGGACTTTAGCAGCTC XhoI CLU (349)
FX29R ATAACTCGAGCTGGTCTTCGCCTTGCGTGAGG XhoI CLU (381)
FX36F ATAGGATCCAGTGGAAGATGCTCAACACC BamHI CLU (349)2.3. Yeast two-hybrid clusterin plasmids
Plasmid pGADT7 AD vector used for the yeast two-hybrid assay
was from Clontech. Human clusterin plasmid (Clone:
HsCD00000240) was from Dana-Farber/Harvard Cancer Center DNA
Resource Core (Cambridge, MA, USA). StrataClone™ PCR Cloning Kit
(pSC-A vector) from Stratagene (La Jolla, CA, USA) was used to clone
PCR fragments.
2.3.1. Clusterin215–449 plasmid pFX48
The pray plasmid pFX48 containing clusterin amino acids 215–449
(clusterin215–449) insert was isolated from the yeast two-hybrid screen
positive clone.
2.3.2. Clusterin α subunit plasmid pFX90
Clusterin α subunit (clusterin228–449) was ampliﬁed by PCR with
primers FX25F and FX22R from a human clusterin plasmid and cloned
to obtain the plasmid pFX89. Plasmid pFX89 was cut with BamHI and
XhoI and the resulting clusterin α subunit was cloned into pGADT7
vector to get the plasmid pFX90.
2.3.3. Clusterin273–449 plasmid pFX64 and clusterin308–449
plasmid pFX73
Clusterin215–449 plasmid pFX48 was cut with EcoRI or BglII to get
rid of the coding region of clusterin 215–272 or 215–307. The resulting
big fragments containing clusterin coding region 273–449 or 308–449
were self ligated to get the plasmid pFX64 or pFX73.
2.3.4. Clusterin320–381 plasmid pFX97
Clusterin320–381 was ampliﬁed by PCR with primers FX27F and
FX29R from a human clusterin plasmid and cloned to obtain plasmid
pFX95. Plasmid pFX95 was cut with BamHI and XhoI and the resulting
Clusterin320–381 was cloned into pGADT7 to obtain the plasmid pFX97.
This Clusterin320–381 contains a helix region predicted from software
PredictProtein [20].
2.3.5. Clusterin314–349 plasmid pFX92
Clusterin314–449 was ampliﬁed by PCR with primers FX28F and
FX28R from a human clusterin plasmid and directly cloned into
pGADT7 to obtain the plasmid pFX92. This clusterin314–449 contains
coiled-coil leucine zipper-like regions [21].
2.3.6. Clusterin349–381 plasmid pFX110
Clusterin349–381 was ampliﬁed by PCR with primers FX36F and
FX29R from a human clusterin plasmid and cloned into pGADT7 to
obtain the plasmid pFX110.
2.3.7. Clusterin375–449 plasmid pFX81
Clusterin375–449 was ampliﬁed by PCR with primers FX23F and
FX22R from pFX64, and cloned to obtain the plasmid pFX79.
Plasmid pFX79 was cut with BamHI and XhoI and the resulting
Clusterin375–449 was cloned into pGADT7 vector to obtain the
plasmid pFX81.
2.3.8. Clusterin β subunit plasmid pFX77
Clusterin β subunit clusterin23–227 was ampliﬁed by PCR with
primers FX21F and FX21R from a human clusterin plasmid and cloned
to obtain the plasmid pFX75. Plasmid pFX75 was cut with BamHI and
XhoI and the resulting clusterin β subunit was cloned into pGADT7
vector to obtain the plasmid pFX77.
2.4. Mammalian cell expression vectors, transfection,
co-immunoprecipitation, gel electrophoresis and Western blot analysis
Plasmid pFX2 containing PrP23–231 was cut with SﬁI+SalI, in-





Protein region Vector Plasmid generated from
pFX1 PRNP (aa 23–231) pGEM3Z
pFX2 PRNP (aa 23–231) pGBKT7
pFX33 PRNP (aa 23–95) PrPc N-terminal pGBKT7
pFX43 PRNP (aa 23–231) pCMV-HA
pFX70 PRNP (aa 95–231) PrPc C-terminal pGBKT7
pFX48 CLU (aa 215–449) Clusterin α subunit pGADT7-Rec Y2H
pFX64 CLU (aa 273–449) Clusterin α subunit pGADT7-Rec pFX48
pFX73 CLU (aa 308–449) Clusterin α subunit pGADT7-Rec pFX48
pFX75 CLU (aa 23–227) Clusterin β subunit pSC-A Human clusterin plasmid
pFX77 CLU (aa 23–227) Clusterin β subunit pGADT7 Human clusterin plasmid
pFX79 CLU (aa 375–449) Clusterin α subunit pSC-A pFX64
pFX81 CLU (aa 375–449) Clusterin α subunit α Helix pGADT7 pFX64
pFX88 CLU (aa 273–449) Clusterin α subunit pCMV-Myc Human clusterin plasmid
pFX89 CLU (aa 228–449) Clusterin α subunit pSC-A Human clusterin plasmid
pFX90 CLU (aa 228–449) Clusterin α subunit pGADT7 Human clusterin plasmid
pFX92 CLU (aa 314–349) Clusterin α subunit coiled-coil leucine zipper-like pGADT7 Human clusterin plasmid
pFX95 CLU (aa 320–381) Clusterin α subunit α Helix pSC-A Human clusterin plasmid
pFX97 CLU (aa 320–381) Clusterin α subunit α Helix pGADT7 Human clusterin plasmid
pFX110 CLU (aa 349–381) Clusterin α subunit α Helix pGADT7 Human clusterin plasmid
pFX111 CLU (aa 23–227) Clusterin β subunit pCMV-Myc Human clusterin plasmid
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Clusterin273–449 PCR product ampliﬁed by primers FX22F and FX22R
from a human clusterin plasmid was cut with BamHI+XhoI, inserted
into mammalian expression vector pCMV-Myc (Clontech) cut with
BamHI+XhoI to obtain the clusterin expression plasmid pFX88.
β subunit clusterin was also cloned into pCMV-Myc to obtain the
expression plasmid pFX111.
HEK 293 cells were maintained in Dulbecco's Modiﬁed Eagle's
Medium supplement with 12% fetal bovine serum. Ten µg of each
plasmid DNA were transfected into 5×105 HEK 293 cells using the
calcium phosphate transfection kit (Invitrogen, Carlsbad, CA, USA).
Cells were harvested 48 h post-transfection in 500 µl of lysis buffer,
and used for co-immunoprecipitationwith themammalian HA-Tag IP/
Co-IP kit (Pierce, Rockford, IL, USA). Proteins co-immunoprecipitated
by anti-HA antibody were subjected to SDS-polyacrylamide gel
electrophoresis on a 10% acrylamide gel, blotted on a nylon
membrane and detected with mouse monoclonal anti-Myc antibody
(Clontech) according to Amersham ECL PlusWestern Blotting Systems
(Piscataway, NJ, USA).
2.5. Circular dichroism analysis
CD spectra in the far-UV region were recorded between 200 nm
and 300 nm on a Jasco J-810 Spectropolarimeter (JASCO, Japan) at
25±0.2 °C in a rectangular quartz cuvette with 2 mm path length. The
bandwidth was 1.0 nmwith a resolution of 0.2 nm and a scan speed of
100 nm/min. CD spectra were accumulated from ten measurements.
The ellipticity of CD spectra is expressed in millidegrees.
To provide comparable CD data, the concentrations of the protein
samples were set as follows: the reference human PrPc sample
(Prionics, Switzerland) comprised of 100 μL of 8 μM PrPc stock
solution in phosphate buffered saline pH 7.4 (PBS) (Quality Biological,
Inc., USA) and 200 μL of PBS buffer. The reference human clusterin
sample (ProSpec, Israel) comprised of 100 μL of 8 μM clusterin stock
solution (ProSpec, Israel) and 200 μL of PBS. The mixed PrPc/clusterin
sample was obtained by adding of 100 μL of PrPc stock solution and
100 μL of clusterin stock solution to 100 μ L of PBS. Human serum
albumin (ALB) essentially fatty acid free (Sigma Chemical Co., USA)
was used in the same experimental conditions and comparable
concentration as a negative control to illustrate a “no-binding”
scenario. CD spectrum of PBS (background) was subtracted from each
protein CD spectra.3. Results
3.1. Yeast two-hybrid screen
The human prion core region PrP23–231, without an N-terminal
signal peptide and the C-terminal hydrophobic peptide, was cloned
into the GAL4 DNA-binding domain bait vector pGBKT7 to create the
bait plasmid pFX2. To isolate the putative prion interacting proteins,
pFX2 was transformed into yeast AH109 and the resulting yeast
AH109 [pFX2] was mated with a pretransformed human adult brain
cDNA yeast library fused to the GAL4 activation domain (AD). The
mating mixture was grown on selection SD medium in the absence of
four nutrients (Leu, Trp, Ade, and His). Prior to performing the Y2H
assay, the bait plasmid pFX2 was not found to spontaneously activate
the reporter genes HIS3 and ADE2. After ﬁve days of growing on the SD
selection medium, 2302 clones were obtained from 2.4×108 screened
human adult brain cDNA clones. Of these, 250 clones were screened
further on X-α-Gal medium and 249 were found to be positive. DNA
from 110 positive clones were ampliﬁed with PCR and sequenced. One
of these positive clones (Y2H3109) was found to encode the
C-terminal region amino acids 215–449 of clusterin gene in the
correct reading frame. One of the plasmids encoding clusterin in the
yeast clone Y2H3109was extracted and designed as pFX48. The pFX48
was reintroduced into yeast Y187 to obtain yeast Y187 [pFX48], and
mated with prion bait yeast AH109 [pFX2]. The resulting yeast was
retested on the SD selection medium, and positive clones were grown.
This re-cloning further conﬁrms the interaction between the PrPc and
clusterin in yeast.
3.2. Clusterin α subunit but not β subunit binds to prion
Plasmid pFX48, isolated from the original yeast two hybrid
screening, contained the entire α subunit of clusterin and additional
13 amino acids (clusterin 215–227) that encode a segment of the
β subunit of clusterin. To determinewhether theα subunit of clusterin
can independently interact with the PrPc, the α subunit region was
ampliﬁed, cloned into a pray pGADT7 vector to obtain pFX90, and
introduced into yeast Y187. The resulting yeast Y187 [pFX90] was
mated with prion bait yeast AH109 [pFX2], and streaked on SD
selection medium. Positive clones were grown up on the SD selection
medium. This result demonstrates the interaction between the PrPc
and theα subunit of clusterin in yeast. In contrast, ampliﬁcation of the
Fig. 2. The prion protein co-immunoprecipitated with clusterin in vivo. HEK293 cells
were transfected with HA-tagged prion plasmid pFX43 and Myc-tagged β subunit
clusterin plasmid pFX111 (Lane 2), HA-tagged prion plasmid pFX43 alone (Lane 3),
Myc-taggedα subunit clusterin plasmid pFX88 alone (Lane 4), HA-tagged prion plasmid
pFX43 and Myc-tagged α subunit clusterin plasmid pFX88 (Lane 5). The cell extracts
were subjected to immunoprecipitation with anti-HA antibody, and analyzed by
anti-Myc antibody in Western blot assay. Lane 1 and 6 contained the same cell extracts
from Lane 2 and 5 respectively without immunoprecipitation with anti-HA antibody.
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obtain pFX77 and testing it in the Y2H assay resulted in no interaction
between the PrPc and β subunit of clusterin in yeast.
3.3. The α helix region of clusterin α subunit binds to prion
To determine the smallest region of clusterin that interacts with
the PrPc, several plasmids were constructed with clusterin sections of
various sizes and tested with the Y2H assay.
The plasmid pFX48 containing the clusterin 215–449 was used
to delete coding regions from N-terminal side to obtain the
clusterin273–449 plasmid pFX64 or clusterin308–449 plasmid pFX73.
Plasmid pFX64 and pFX73 were introduced into yeast Y187
respectively and mated with prion pray yeast AH109 [pFX2]; the
resulting yeast was shown to be able to grow on SD selection
medium. These results indicate that both the clusterin C-terminal
273–449 region and an even shorter region 308–449 are able to
interact with PrPc.
When the software PredictProtein [20] was used for clusterin
sequence analysis, it revealed two α helix regions that are encoded
around 320–374 and 428–447 respectively. To test whether the α
helix region is essential for the interaction between clusterin and the
PrPc, both clusterin 320–381 and clusterin 375–449 regions were
ampliﬁed with PCR and cloned into pGADT7 to obtain the plasmid
pFX97 and pFX81, respectively. Plasmid pFX97 and pFX81 were
introduced into yeast Y187 and mated with prion pray yeast AH109
[pFX2]; the resulting yeast from mating with pFX97 but not pFX81
was capable of growing after four days on the SD selection medium.
These observations indicate that the 62 amino acids of the clusterin α
helix section 320–381 is able to interact with PrPc while a separate
C-terminal α helix region 428–447 is not. Most likely there are
additional factors besides the helix structure that facilitate the
interaction with the PrPc.
Previously, the C-terminal coiled-coil domain of the nuclear form
of clusterin was found to be essential for binding to Ku70 protein
[21]. We ampliﬁed the coiled-coil domain region of clusterin314–349
and cloned into pGADT7 to obtain the plasmid pFX92. Upon testing
with prion AH109 [pFX2] by the Y2H assay, it did not bind to the
PrPc. This result suggests that a different mechanism besides the
coiled-coiled domain is involved in the interaction of clusterin with
PrPc.
The clusterin α helix section 320–381 (pFX97) is able to interact
with PrPc, but not through the coiled-coil domain region of this α
helix section 314–349 (pFX92). To test whether the remaining regionFig. 1. The prion protein interacts with the clusterin α subunit in a yeast two-hybrid
assay. (1) Prion core region [pFX2]. (2) Prion N-terminal region [pFX33]. (3) Prion
C-terminal region [pFX70]. (4) Control vector without prion [pGBKT7]. All the yeast
were grown on selection SDmedium in the absence of four nutrients (Leu, Trp, Ade, and
His).can bind to PrPc, clusterin 349–381 was ampliﬁed, cloned into
pGADT7 to obtain the plasmid pFX110 and tested with prion AH109
[pFX2] by Y2H assay. Clusterin 349–381 was not able to bind to the
PrPc. This demonstrated that the 62 amino acids of the clusterin α
helix section 320–381 is the shortest region that is able to interact
with PrPc.
3.4. Prion N-terminal region PrP23–95 and C-terminal region PrP95–231
bind to clusterin
Prion plasmid pFX2which contains themature prion coding region
23–231 was used to identify the clusterin as a prion ligand in the
original Y2H library screening. To further characterize the prion region
responsible for the clusterin binding, the N-terminal region PrP23–95
plasmid pFX33 and C-terminal region PrP95–231 plasmid pFX70 were
constructed from pFX2, introduced into yeast AH109, mated with
yeast Y817[pFX90] which contains the clusterin α subunit, and tested
on SD selection medium. Both of AH109 [pFX33] and AH109 [pFX70]
mated with Y187 [pFX90] were able to grow up on SD selection
medium after three days (Fig. 1). Control AH109 [pGBKT7] mated with
Y187 [pFX90] was not able to grow on SD-His-Leu-Trp-Ade selection
medium, but was able to grow on SD-Leu-Trp medium. These data
suggests that either the N-terminal region PrP23–95 or the C-terminal
region PrP95–231 is able to interact with clusterin. A similar interaction
of chaperone protein Hsp60 and PrPc was reported in a Syrian golden
hamster [8]. However, only the region represented by amino acids 180
to 210, but not the N-terminal region of Syrian golden hamster PrPc
was involved in the binding to Hsp60. This suggests that there is a
different mechanism involved in the chaperone protein clusterin and
Hsp60 binding of human PrPc.
3.5. PrPc interacts with clusterin in mammalian cells
To examine whether PrPc can interact with clusterin in
vivo, HA-PrP23–231 plasmid pFX43 and clusterin α subunit c-Myc--
clusterin273–449 plasmid pFX 88 were cotransfected into HEK293 cells,
grown and ﬁnally lysed. The cell extracts were co-immunoprecipi-
tated with an anti-HA antibody and the immunoprecipitates were
separated on Western blots. Myc-tagged clusterin co-immunopreci-
pitated with HA-tagged PrPc and was detected by anti-Myc antibody
in Western blots (Fig. 2, Lane 5). No signal was detectable in cells
transfected with Myc-tagged clusterin alone (Fig. 2, Lane 4) or HA-
tagged prion alone (Fig. 2, Lane 3). Similar co-immunoprecipitation
was performed for clusterin β subunit and PrPc but no signal for the
clusterin β subunit was detectable (Fig. 2, Lane 2). Our data thus show
that PrPc can interact with the clusterin α subunit but not the β
subunit, in yeast and inmammalian cells. This result is consistent with
previous studies in mammalian system in which clusterin was co-
puriﬁed with PrPc from ram epididymal ﬂuid [17] and was cross-
linked with PrPc in a living mouse brain [18].
Fig. 3. CD characterization of clusterin (CLU) interactions with PrPc in vitro. (A) CD spectra of CLU, ALB, and CLU+ALB mixture in PBS. (B) CD spectra of PrPc, CLU, a superposition
(SUM) of the individual CLU and PrPc spectra, and experimental CD spectrum of CLU+PrPc mixture in PBS.
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The in vitro interactions between clusterin and PrPc were
evaluated by far-UV CD spectrometry. CD spectroscopy provides a
non-invasive spectral analysis which is particularly sensitive to
protein conformational changes and thus, may provide a deeper
insight into protein–protein interactions. As a negative control we
utilized mixed samples of human albumin (ALB) with both clusterin
and PrPc (experimental data for ALB and clusterin are shown in
Fig. 3A) that illustrate a “no-binding” case for which CD intensity of
the mixed sample is in an excellent agreement with a mathematical
sum of the CD intensities of each individual protein in the mixture.
Fig. 3B shows far-UV CD spectra of clusterin and PrPc alone in
aqueous solution (pH 7.4) with characteristic bands at 208 nm and
220 nm typical for α-helical structure. Similarly to the results shown
in Fig. 3A, the absence of interactions between clusterin and PrPc
should be reﬂected also by an additive type CD spectrum of the
mixed sample. The thin grey trace on Fig. 3B represents a
superposition of the CD spectra of PrPc and clusterin (shown in
blue and purple) that was projected as a mathematical sum of both
spectra and which would be evident if the proteins do not interact
but co-exist independently in the same solution. However, the
experimental CD spectrum of the mixed sample clusterin+PrPc was
substantially different. Two kinds of signiﬁcant CD spectral changes
were observed after the PrPc was mixed with clusterin. First, the CD
intensity of the PrPc+clusterin mixed sample dropped below the
intensities of each individual spectrum (blue and purple curves) and
it further contracted over time during the next 35 min. For clarity,
only 60 min spectrum is shown in Fig. 3B (a thick red curve). This
observation reﬂects signiﬁcant conformational changes that pro-
ceeded over time upon protein–protein interactions until a certain
conformational equilibrium was achieved. Second, the change of the
shape of PrPc+clusterin CD spectrum by ﬂattening of 208 nm band
clearly reﬂects the alterations in protein helicity upon protein–
protein interactions, thus suggesting that the clusterin and PrPc do
interact in vitro.
4. Discussion
Previously, several groups have used the Y2H assay to screen prion
binding proteins in yeast cotransformed with cDNA library and PrPc
DNA. In this study, we employed a new Y2H assay in which a
pretransformed cDNA library and the prion pray plasmid were
introduced by mating instead of cotransformation. Our data demon-
strates an interaction between prion and clusterin proteins using the
Y2H assay and through a co-immunoprecipitation in transfected cells.In addition, CD spectrum analysis of the in vitro interaction between
PrPc and clusterin provides clear evidence of conformational changes
when PrPc and clusterin are mixed together.
Clusterin is a widely expressed glycoprotein, and its major
secretory form is generated from cleavage of the full length protein at
peptide bond Arg227–Ser228 to yield α and β polypeptides that
are linked by ﬁve disulphide bonds to form the heterodimer. We
found that the PrPc interacts only with the α but not with the
β polypeptides. Furthermore, clusterin also exists as a nuclear form
from alternative splicing [21], but this form is unlikely to interact with
PrPc based on the subcellular distribution of the PrPc. Most of the PrPc
are localized on the cell membranes, where they are attached to the
lipid bilayer via a C-terminal GPI anchor, although minute amounts of
PrPc may exist as two transmembrane variants (NtmPrP and CtmPrP)
[22,23].
Our ﬁndings indicate that speciﬁc regions of clusterin interact with
the PrPc and are consistent with the following previous evidence
pointing to clusterin as one of PrPc ligands. First, clusterin was found
to prevent the aggregation of prion fragment 106–126 in vitro [24].
Second, clusterin was co-puriﬁed with soluble PrPc from ram
epididymal ﬂuid [17]. Third, clusterin was found residing in the
molecular microenvironment of the PrPc in living mouse brain
through time-controlled transcardiac perfusion cross-liking [18].
Fourth, clusterin has been shown to be associated with PrPc in TSE
diseases. In the CNS and PNS of infected animals and humans,
clusterin was co-localized with the extracellular plaque-type prion
deposits, and its expression was increased in association with
abnormal prion deposits [25–29]. Finally, clusterin knockout mice
inoculated with BSE agent had an increased incubation time prior to
symptomdevelopment in comparisonwithwild-typemice [19] which
suggest that the pathophysiologic mechanism of this disease involves
clusterin in some manner.
Clusterin is implicated in various cell functions that are involved in
apoptosis, cell cycle control, DNA repair, lipid transportation, cell
adhesion, and in diseases such as cancer, Alzheimer's disease and
other neurodegenerative diseases [30–33]. Clusterin has been pro-
posed to be a secreted mammalian chaperone [34]. Consistent with its
putative extracellular chaperone function, clusterin prevents precipi-
tation of denatured proteins in vitro [35] andmediates the transport of
the Alzheimer's disease Aβ peptide from the blood to the brain across
the blood-brain barrier through the clusterin receptor [36]. Interes-
tingly, there is 25% similarity between residues of 286–343 of clusterin
and αB-crystallins [34]. αB-crystalline [9] and other chaperone
proteins, Hsp60 [8] and Rdj2 [10], have been shown to directly
interact with PrPc. In fact, αB-crystalline was identiﬁed as prion
binding protein in the 110 sequenced clones obtained in our yeast
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underlying mechanisms involve a conformational change of normally
expressed proteins without an alteration in their amino acid sequence
[37,38]. The involvement of clusterin in both of these neurodege-
nerative diseases raises the possibility of common pathophysiologic
mechanisms.
Currently, there is no treatment for TSE diseases. One rational
approach to therapy is to develop a method(s) to speciﬁcally
eliminate the PrPc or its ligands. Inhibition of PrPtse formation in
chronically prion-infected cells has been achieved by lentiviral gene
transfer of the prion gene containing dominant negative mutations
[39]. In addition, clusterin knockout mice inoculated with BSE agent
had increased incubation time in comparison with wild-type mice
[19]. These observations suggest that therapeutic targeting of the
PrPc or its ligands, such as clusterin, could prevent or delay the onset
of prion diseases. Phase II studies for clusterin as a therapeutic target
by antisense clusterin oligodeoxynucleotides in malignancies are
underway [40–42]. It is possible that the clinical modulation of
clusterin may also be an effective therapeutic target for human prion
diseases.
In conclusion, we conﬁrmed that clusterin is a ligand for human
PrPc. Elucidation of the molecular mechanism of the interaction
between prion and clusterin proteins will help to further understand
the pathogenesis of TSE diseases and potentially provide future
therapeutic approaches.References
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